Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
Korro Bio and Frequency Therapeutics’ Merger Agreement
Gurnet Point Capital’s Acquisition of Paratek Pharmaceuticals
Latham & Watkins advises Gurnet Point Capital in acquisition of Paratek Pharmaceuticals. Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Cordis’ Acquisition of MedAlliance
Latham & Watkins represented MedAlliance in the transaction. Swiss-based medical technology company MedAlliance announced it has entered into an agreement with Cordis for an acquisition which includes...
MeiraGTx’s Growth Financing Agreement with Perceptive Advisors
Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates...
Chinook Therapeutics’ $105 Million Public Offering
Latham & Watkins represented the underwriters in the offering. Chinook Therapeutics, Inc. (Nasdaq: KDNY) has announced the pricing of its underwritten public offering of 6,428,572 shares...